Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.83 |
| ▸ | TACR2 | P21452 | 1/20 | 0.83 |
| ▸ | CNR2 | P34972 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1377402 | 0.91 | CNR1 (0.73) | CNR1TACR2CNR2 | |
| SCHEMBL5271693 | 0.91 | CNR1 (1.00) | CNR1TACR2CNR2 | |
| SCHEMBL1377255 | 0.91 | CNR1 (1.00) | CNR1TACR2CNR2 | |
| SCHEMBL1377250 | 0.91 | CNR1 (1.00) | CNR1TACR2CNR2 | |
| SCHEMBL1376708 | 0.91 | CNR1 (1.00) | CNR1TACR2CNR2 | |
| SCHEMBL1380739 | 0.90 | CNR1 (0.82) | CNR1TACR2CNR2 | |
| SCHEMBL5271821 | 0.90 | CNR1 (0.82) | CNR1TACR2CNR2 | |
| SCHEMBL1379460 | 0.89 | CNR1 (0.85) | CNR1TACR2CNR2 | |
| SCHEMBL1379459 | 0.89 | CNR1 (0.85) | CNR1TACR2CNR2 | |
| SCHEMBL1377904 | 0.88 | CNR1 (0.91) | CNR1TACR2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4712865-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| EP-1868999-B1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | claimed |
| EP-1868999-A1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | F. Hoffmann-Roche AG (CH) | 2007-12-26 | — | — | EP | claimed |
| US-7229999-B2 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-06-12 | — | — | US | claimed |
| US-20060229326-A1 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | US | claimed |
| WO-2006106054-A1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | claimed |
| EP-2074096-B1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | HOFFMANN LA ROCHE (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-8188093-B2 | Pyrazinecarboxamide derivatives as HDL-cholesterol raising agents | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2450350-A1 | 3-Pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents | F. Hoffmann-La Roche AG (CH) | 2012-05-09 | — | — | EP | disclosed |
| US-20100267745-A1 | 3-Pyridinecarboxamide Derivatives as HDL-Cholesterol Raising Agents | ANDJELKOVIC MIRJANA | 2010-10-21 | — | — | US | disclosed |
| US-7812028-B2 | 3-pyridinecarboxamide derivatives as HDL-cholesterol raising agents | HOFFMANN-LA ROCHE INC. (US) | 2010-10-12 | — | — | US | disclosed |
| EP-2074096-A1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| EP-1868999-B1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20090143409-A1 | 3-PYRIDINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | ANDJELKOVIC MIRJANA | 2009-06-04 | — | — | US | disclosed |
| US-20080085906-A1 | 3-Pyridinecarboxamide derivatives as HDL-cholesterol raising agents | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | US | disclosed |
| WO-2008040651-A1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | WO | disclosed |
| EP-1868999-A1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | F. Hoffmann-Roche AG (CH) | 2007-12-26 | — | — | EP | disclosed |
| US-7229999-B2 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20060229326-A1 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | US | disclosed |
| WO-2006106054-A1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085906-A1 | 3-Pyridinecarboxamide derivatives as HDL-cholesterol raising agents | CETP, APOB, LDLR | CNR1 69/4885TACR2 3356/4885CNR2 177/4885 |
| US-20060229326-A1 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | CNR1, CNR2, GPR119 | CNR1 1/4885TACR2 186/4885CNR2 2/4885 |
| US-20090143409-A1 | 3-PYRIDINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | CETP, APOB, LDLR | CNR1 69/4885TACR2 3356/4885CNR2 177/4885 |
| US-20100267745-A1 | 3-Pyridinecarboxamide Derivatives as HDL-Cholesterol Raising Agents | CETP, APOB, LDLR | CNR1 69/4885TACR2 3356/4885CNR2 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.